GO
| HSI1 | 24,448.95 | -32.91 | 173.71B |
| HSCEI1 | 8,260.15 | -13.95 | 54.80B |
| Back Zoom + Zoom - Block Traded | |
|
SBP GROUP (01177.HK) Announces Phase II Clinical Data for TQ-A3334
2026-11-09 09:59:01 SBP GROUP (01177.HK) announced that TQ-A3334 (a TLR7 agonist) zb2, a Class 1 innovative drug independently developed by its subsidiary Chia Tai Tianqing, presented Phase II clinical study results in an oral presentation at the late-breaking abstract parallel session of the American Association for the Study of Liver Diseases (AASLD) annual meeting in 2026. The study was a double-blind, randomized, placebo-controlled Phase II clinical trial. The data released this time covered the nucleos(t)ide analogues (NAs)-experienced cohort. As of October 15, a total of 81 patients had been enrolled in the NAs-experienced cohort, including 12, 24 and 24 patients in the low-, medium- and high-dose groups respectively, while the placebo group included 21 patients. Clinical data showed that in the high-dose group, the average decline in HBsAg from baseline at Week 24 and Week 48 was 1.3244 log10 IU/mL and 1.8103 log10 IU/mL respectively, with both differences showing statistical significance compared with the placebo group. The company stated that based on previous and current study results, TQ-A3334 obtained Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration in October this year. The company expects the 48-week results to provide further support for subsequent clinical development, supporting the further development of TQ-A3334 as an oral immunomodulatory drug and offering a new potential treatment option for functional cure of chronic HBV infection. (gc/j)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |